Dr. MD PhD Alexander Gebauer
CEO Secarna Pharmaceuticals GmbH & Co. KG

 

Topic: LNAplus™ antisense oligonucleotides are effective and safe therapeutic modalities for a variety of diseases

The third generation of antisense molecules provides drug developers with a powerful intervention option. Secarna operates a development platform that allows lead candidates against mRNA targets to be rationally identified in a semi-industrial process. This includes in-house bioinformatics analysis, high-throughput screening, and efficacy and safety assays. Secarna has six ongoing partnerships with companies and over ten academic collaborations.

Prof. Magdalena Götz
Director of the Institute of Stem Cell Research at Helmholtz Zentrum München and Chair of Physiological Genomics at Ludwig-Maximilians-Universität Munich

 

Topic: A new approach to neuronal replacement therapy

Direct reprogramming of local glial cells into new neurons is a new promising approach to replace dead neurons. This approach was discovered several years ago by Prof. Goetz. She will present the current status of this innovative approach to neuronal replacement therapy at the IZBrunch.